MusclePharm Performance
The company secures a Beta (Market Risk) of 0.0, which conveys not very significant fluctuations relative to the market. the returns on MARKET and MusclePharm are completely uncorrelated.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days MusclePharm has generated negative risk-adjusted returns adding no value to investors with long positions. Even with relatively invariable basic indicators, MusclePharm is not utilizing all of its potentials. The current stock price agitation, may contribute to short-term losses for the retail investors. ...more
| Begin Period Cash Flow | 2 M | |
| Total Cashflows From Investing Activities | -2000.00 |
MusclePharm |
MusclePharm Relative Risk vs. Return Landscape
If you would invest (100.00) in MusclePharm on October 11, 2024 and sell it today you would earn a total of 100.00 from holding MusclePharm or generate -100.0% return on investment over 90 days. MusclePharm is currently producing negative expected returns and takes up 0.0% volatility of returns over 90 trading days. Put another way, 0% of traded pink sheets are less volatile than MusclePharm, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
MusclePharm Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for MusclePharm's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as MusclePharm, and traders can use it to determine the average amount a MusclePharm's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| MSLPQ |
Based on monthly moving average MusclePharm is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of MusclePharm by adding MusclePharm to a well-diversified portfolio.
MusclePharm Fundamentals Growth
MusclePharm Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of MusclePharm, and MusclePharm fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on MusclePharm Pink Sheet performance.
| Revenue | 50.04 M | |||
| EBITDA | (7.07 M) | |||
| Total Debt | 10.71 M | |||
| Cash Flow From Operations | (8.04 M) | |||
| Total Asset | 11.21 M | |||
| Retained Earnings | (205.54 M) | |||
About MusclePharm Performance
Assessing MusclePharm's fundamental ratios provides investors with valuable insights into MusclePharm's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the MusclePharm is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Things to note about MusclePharm performance evaluation
Checking the ongoing alerts about MusclePharm for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for MusclePharm help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| MusclePharm is not yet fully synchronised with the market data | |
| MusclePharm has some characteristics of a very speculative penny stock | |
| MusclePharm has a very high chance of going through financial distress in the upcoming years | |
| The company reported the revenue of 50.04 M. Net Loss for the year was (12.87 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| MusclePharm generates negative cash flow from operations |
- Analyzing MusclePharm's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether MusclePharm's stock is overvalued or undervalued compared to its peers.
- Examining MusclePharm's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating MusclePharm's management team can have a significant impact on its success or failure. Reviewing the track record and experience of MusclePharm's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of MusclePharm's pink sheet. These opinions can provide insight into MusclePharm's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Other Consideration for investing in MusclePharm Pink Sheet
If you are still planning to invest in MusclePharm check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the MusclePharm's history and understand the potential risks before investing.
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Stocks Directory Find actively traded stocks across global markets | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk |